Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Laboratory of Clinical Microbiology and Virology, Polyclinic Tor Vergata Foundation, Rome, Italy.
J Viral Hepat. 2020 Jan;27(1):4-12. doi: 10.1111/jvh.13183. Epub 2019 Aug 13.
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are classified as oncogenic human viruses. Chronic HBV and HCV infections are associated with higher risk of haematological malignancy development. Direct and indirect oncogenic mechanisms have been demonstrated for both HBV and HCV in several studies. HCV and overt/occult HBV infections in patients with oncohaematological disease constitute an impediment and a threat during immunosuppressive chemotherapy treatment. We review the HBV and HCV oncogenic mechanisms and the impact and the safety of antiviral treatment in patients with haematological malignancies.
乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)被归类为致癌人类病毒。慢性 HBV 和 HCV 感染与血液系统恶性肿瘤发展的风险增加相关。多项研究表明,HBV 和 HCV 均具有直接和间接致癌机制。在接受免疫抑制化疗的血液系统恶性肿瘤患者中,HCV 和显性/隐匿性 HBV 感染构成了障碍和威胁。我们回顾了 HBV 和 HCV 的致癌机制,以及抗病毒治疗对血液系统恶性肿瘤患者的影响和安全性。